This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Apr 6;381(9873):1163-5.

doi: 10.1016/S0140-6736(12)61965-5. Epub 2013 Feb 20.

First-line treatment of indolent lymphoma: axing CHOP?

Caron A Jacobson¹, Arnold S Freedman

Affiliations

PMID: 23433738
DOI: 10.1016/S0140-6736(12)61965-5

Comment

First-line treatment of indolent lymphoma: axing CHOP?

Caron A Jacobson et al. Lancet. 2013.

. 2013 Apr 6;381(9873):1163-5.

doi: 10.1016/S0140-6736(12)61965-5. Epub 2013 Feb 20.

Authors

Caron A Jacobson¹, Arnold S Freedman

Affiliation

¹ Dana-Farber Cancer Institute, Boston, MA 02215, USA.

PMID: 23433738
DOI: 10.1016/S0140-6736(12)61965-5

No abstract available

PubMed Disclaimer

Comment on

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program